Latest Market Access News

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Aristocrat Leisure has delivered a robust FY25 performance with double-digit growth in earnings and revenue, underpinned by market share gains and strategic portfolio realignment. The company also returned $1.4 billion to shareholders through dividends and buy-backs.

American West Metals has begun trading on the OTCQB Venture Exchange, boosting its visibility among US investors and signaling potential future listings on major US exchanges amid rising demand for domestic critical minerals.

Caravel Minerals has signed a non-binding MOU with Adani’s Kutch Copper to jointly advance the Caravel Copper Project toward a 2026 Final Investment Decision, exploring funding and offtake agreements.

Group 6 Metals has materially improved its debt position by converting warrants under its April 2025 recapitalisation plan, signaling renewed shareholder confidence and operational momentum.

Austral Resources Australia Ltd has successfully completed a $40 million capital raise and is reinstated to ASX trading, positioning itself as a mid-tier copper producer with a dual-hub operation in Queensland.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

NuEnergy Gas Limited has announced a $4.62 million entitlement offer, primarily to fund early gas sales and development of its Indonesian coal bed methane assets. The offer is partially underwritten by a major shareholder and supports key milestones in the company’s transition to commercial production.

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.